Next Article in Journal
Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer’s Disease
Previous Article in Journal
High Level of Pre-Treatment HIV-1 Drug Resistance and Its Association with HLA Class I-Mediated Restriction in the Pumwani Sex Worker Cohort
Previous Article in Special Issue
The Reservoir of Persistent Human Papillomavirus Infection; Strategies for Elimination Using Anti-Viral Therapies
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Special Issue: HPV and HPV Vaccines

Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin 9054, New Zealand
Viruses 2022, 14(2), 274; https://doi.org/10.3390/v14020274
Submission received: 25 January 2022 / Accepted: 27 January 2022 / Published: 28 January 2022
(This article belongs to the Special Issue HPV and HPV Vaccine)
Our fundamental understanding of papillomaviruses and their interactions with their host, including their role in cancer and how the immune system responds to them, has made the elimination of cervical cancer a realistic global health goal. Articles and reviews in this Special Issue explore aspects of papillomavirus infection and latency, immunity, vaccination and self-sampling that inform this global health goal of elimination. This Special Issue includes excellent comprehensive reviews on the role of papillomavirus in carcinogenesis and on the viral life cycle in the cervix. Papillomavirus is increasingly associated with head and neck cancers and has been linked to the causality of cutaneous squamous cell carcinoma. This Special Issue includes reviews and original articles that extend our understanding of papillomavirus carcinogenesis at these sites. The thought-provoking review by Zheng et al. discusses viral elimination through the use of anti-viral therapies, highlighting a gap in our armoury—therapeutic approaches, either through drugs or immunisation, that can eliminate active and latent infection. The various contributions in this Special Issue highlight the need to continue to advance our understanding of papillomavirus and its interaction with its host, and how the host responds to it, so that we are able to continue to improve and refine our health interventions against it. I sincerely thank all authors who have contributed to this Special Issue, “HPV and HPV vaccines”.

Funding

This research received no external funding.

Conflicts of Interest

The author declares no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hibma, M. Special Issue: HPV and HPV Vaccines. Viruses 2022, 14, 274. https://doi.org/10.3390/v14020274

AMA Style

Hibma M. Special Issue: HPV and HPV Vaccines. Viruses. 2022; 14(2):274. https://doi.org/10.3390/v14020274

Chicago/Turabian Style

Hibma, Merilyn. 2022. "Special Issue: HPV and HPV Vaccines" Viruses 14, no. 2: 274. https://doi.org/10.3390/v14020274

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop